VRX (Valeant Pharmaceu)
All Pro Portfolios with VRX
- Total Pro Portfolios with VRX:
- VA Partners - ValueAct
- show more
- 1
All Do-It-Yourself Portfolios with VRX
- Total Do-It-Yourself Portfolios with VRX:
- Short Squeezes
- A McCord Portfolio 1
- hogdoc Portfolio 1
- Parkinson's Treatment Stocks
- thomboy
- hotelexec1
- gmarlow Portfolio 1
- Happy Acres
- Barron's Insider Purchases 6-21-2008
- RAPTOR SPRTD-1010081910
- Barron's Interview Berwyn Income Fund
- Barron's Activist Stocks 5-23-2009
- Top 10 Insider Purchases: June 29
- show more
- 25
- chriseco Portfolio 1
- martynorm Portfolio 1
- Stockerblog.com Parkinson's Stocks
- CB_Health
- neilgass Portfolio 1
- Sun's
- Trader Doug
- Barron's Insider Purchases 6-07-2008
- Barron's Insider Purchases 7-05-2008
- Peter's Current Portfolio
- Barron's Insider Purchases 5-23-2009
- Barron's Smart Money Stock Picks
- News For Selected Stock
- Related stories on theStreet.com
- videos related to etf's
- No videos found
- blogs related to etf's
- No blogs found
Why I Love This Stock |
|
Date:06 30 09 |
|
1. "BO" bought 51,600 shares, worth about $1.3 million. |
|
Not yet rated
Rate now:
|
|
By:barrons3 |
Date:05 23 09 |
ValueAct Capital has a seat on Valeant's board and has been instrumental in effecting an ongoing restructuring of the company. From May 7 through May 15, ValueAct purchased 2.6 million common shares, bringing its ownership to 19.3%. On May 15, Valeant amended its poison pill so investors like ValueAct could own up to 30% of its common. |
|
Not yet rated
Rate now:
|
|
By:barrons3 |
Date:04 18 09 |
In the drug sector, the fund last fall scooped up Valeant Pharmaceuticals'(VRX) 3% convertible due Aug. 16, 2010. The specialty-pharmaceuticals company has more cash than debt, and was actively buying back its debt late last year. Yet, Berwyn was able to capture yields close to 15%. |
|
Not yet rated
Rate now:
|
|
By:luckyone3 |
Date:01 03 09 |
Speculation |
|
Not yet rated
Rate now:
|
|
By:mdkretz |
Date:03 10 08 |
Retigabine approval |
|
Not yet rated
Rate now:
|
|
By:Pro |
Date:11 30 -1 |
Valeant Pharma (VRX) was upgraded to Peer Perform, Bear Stearns said. Gross margins should improve, along with the likelihood of a successful RET launch. |
|
Not yet rated
Rate now:
|
|
By:Joelle |
Date:07 25 07 |
Helps with Parkinsons. |
|
Not yet rated
Rate now:
|
|
By:Guest |
Date:04 26 07 |
Valeant Pharmaceuticals International (VRX) markets Zelapar® [selegiline HCl] Orally Disintegrating Tablets, a once-daily adjunct therapy for Parkinson’s disease patients being treated with levodopa/carbidopa. Forward P/E of 16.6 and a PEG of .8. Yields 1.7%. |
|
Not yet rated
Rate now:
|
|
Why I Hate This Stock |
|
| Comments not available |